Cherie Lin
Research Subjects
Cherie Lin has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alison J. Wu
University of Toronto 1 MD Program, Temerty Faculty of Medicine Toronto, Canada
10 shared publications - Benjamin Haibe-Kains
Princess Margaret Cancer Center, University Health Network
10 shared publications - Farnoosh Abbas-Aghababazadeh
Princess Margaret Cancer Centre 3 Toronto, Canada
10 shared publications - Fei-Fei Liu
Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
10 shared publications - Jennifer Yin Yee Kwan
Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
10 shared publications - Jie Su
Department of Biostatistics, the Princess Margaret Cancer Centre/University of Toronto, Canada
10 shared publications
Latest Publications
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Table 4 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Net reclassification improvement by IFNα2a.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 4 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Net reclassification improvement by IFNα2a.
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Lymphedema is a chronic complication of breast cancer treatment, and early intervention is crucial to reduce morbidity. This study evaluated the role of blood-based cytokine biomarkers in the prognostication of breast cancer–related lymphedema (BCRL) to improve risk prediction. A secondary analysis of inflammatory biomarkers for BCRL was performed using a previously published cohort of 147 patients with breast cancer who had undergone serum cytokine profiling during their treatment at the Princess Margaret Cancer Centre from 2010 to 2014. Prognostic cytokine variables for lymphedema were selected by regression analysis and independence from known clinical risk factors. Regression-based modeling was employed to integrate prognostic variables for the prediction of lymphedema occurrence. We identified the immunostimulatory cytokine IFNα2A as a potential biomarker for lymphedema development [OR, 3.10; 95% confidence interval (CI), 1.05–9.51; P = 0.042], independent from known clinical risk factors. Furthermore, Kaplan–Meier analysis demonstrated 3-year lymphedema-free survival of 95% (90%–100%) versus 85% (77%–94%) for below versus above median concentrations of IFNα2A (P = 0.026). In combination with an established clinical risk regression-based model, patients identified as high risk based on clinical factors alone were able to be correctly reclassified as low risk by IFNα2A in 31% (eight of 26) of cases. Our combined logistic regression model using both IFNα2A and clinical risk score achieved an AUC of 0.895 (95% CI, 0.796–0.971) and Brier score of 0.101 (95% CI, 0.061–0.149), representing a favorable improvement compared with the logistic regression model using clinical risk factors alone. IFNα2A in combination with established clinical risk factors may be useful for improving BCRL prognostication.Significance:The cytokine IFNα2A was identified as a potentially complementary biomarker to improve the stratification of high- and low-risk patients for BCRL. This will help enable earlier intervention to reduce long-term morbidity for those at high risk for lymphedema while minimizing burdensome interventions for those at low risk.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Lymphedema is a chronic complication of breast cancer treatment, and early intervention is crucial to reduce morbidity. This study evaluated the role of blood-based cytokine biomarkers in the prognostication of breast cancer–related lymphedema (BCRL) to improve risk prediction. A secondary analysis of inflammatory biomarkers for BCRL was performed using a previously published cohort of 147 patients with breast cancer who had undergone serum cytokine profiling during their treatment at the Princess Margaret Cancer Centre from 2010 to 2014. Prognostic cytokine variables for lymphedema were selected by regression analysis and independence from known clinical risk factors. Regression-based modeling was employed to integrate prognostic variables for the prediction of lymphedema occurrence. We identified the immunostimulatory cytokine IFNα2A as a potential biomarker for lymphedema development [OR, 3.10; 95% confidence interval (CI), 1.05–9.51; P = 0.042], independent from known clinical risk factors. Furthermore, Kaplan–Meier analysis demonstrated 3-year lymphedema-free survival of 95% (90%–100%) versus 85% (77%–94%) for below versus above median concentrations of IFNα2A (P = 0.026). In combination with an established clinical risk regression-based model, patients identified as high risk based on clinical factors alone were able to be correctly reclassified as low risk by IFNα2A in 31% (eight of 26) of cases. Our combined logistic regression model using both IFNα2A and clinical risk score achieved an AUC of 0.895 (95% CI, 0.796–0.971) and Brier score of 0.101 (95% CI, 0.061–0.149), representing a favorable improvement compared with the logistic regression model using clinical risk factors alone. IFNα2A in combination with established clinical risk factors may be useful for improving BCRL prognostication.Significance:The cytokine IFNα2A was identified as a potentially complementary biomarker to improve the stratification of high- and low-risk patients for BCRL. This will help enable earlier intervention to reduce long-term morbidity for those at high risk for lymphedema while minimizing burdensome interventions for those at low risk.
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
IFNα2 levels in patients with breast cancer. Preradiotherapy IFNα2 was measured in 62 patients with breast cancer. Patients were grouped by their lymphedema (LE) status at 18 months after cancer treatment. Data are plotted as median with IQR. Two-tailed P value is 0.157 (Mann–Whitney test).
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
IFNα2 levels in patients with breast cancer. Preradiotherapy IFNα2 was measured in 62 patients with breast cancer. Patients were grouped by their lymphedema (LE) status at 18 months after cancer treatment. Data are plotted as median with IQR. Two-tailed P value is 0.157 (Mann–Whitney test).
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Table S1. Summary of baseline serum cytokine levels measured at pre-radiotherapy.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Table S1. Summary of baseline serum cytokine levels measured at pre-radiotherapy.
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Identification of redundant cytokines.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Identification of redundant cytokines.
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Univariate logistic regression of candidate cytokines for lymphedema occurrence.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Univariate logistic regression of candidate cytokines for lymphedema occurrence.
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Clinical characteristics of the study population.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Clinical characteristics of the study population.
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Table 5 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Performance comparison of logistic regression models to determine the additive value of IFNα2A.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 5 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Performance comparison of logistic regression models to determine the additive value of IFNα2A.
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Kaplan–Meier curve of LFS by IFNα2A. A median threshold was used to define the high and low groups by IFNα2A level. Log-rank P value is 0.026.
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Kaplan–Meier curve of LFS by IFNα2A. A median threshold was used to define the high and low groups by IFNα2A level. Log-rank P value is 0.026.
- Open Access
- 1 March 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (3) , 456-465
Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Lymphedema is a chronic complication of breast cancer treatment, and early intervention is crucial to reduce morbidity. This study evaluated the role of blood-based cytokine biomarkers in the prognostication of breast cancer–related lymphedema (BCRL) to improve risk prediction. A secondary analysis of inflammatory biomarkers for BCRL was performed using a previously published cohort of 147 patients with breast cancer who had undergone serum cytokine profiling during their treatment at the Princess Margaret Cancer Centre from 2010 to 2014. Prognostic cytokine variables for lymphedema were selected by regression analysis and independence from known clinical risk factors. Regression-based modeling was employed to integrate prognostic variables for the prediction of lymphedema occurrence. We identified the immunostimulatory cytokine IFNα2A as a potential biomarker for lymphedema development [OR, 3.10; 95% confidence interval (CI), 1.05–9.51; P = 0.042], independent from known clinical risk factors. Furthermore, Kaplan–Meier analysis demonstrated 3-year lymphedema-free survival of 95% (90%–100%) versus 85% (77%–94%) for below versus above median concentrations of IFNα2A (P = 0.026). In combination with an established clinical risk regression-based model, patients identified as high risk based on clinical factors alone were able to be correctly reclassified as low risk by IFNα2A in 31% (eight of 26) of cases. Our combined logistic regression model using both IFNα2A and clinical risk score achieved an AUC of 0.895 (95% CI, 0.796–0.971) and Brier score of 0.101 (95% CI, 0.061–0.149), representing a favorable improvement compared with the logistic regression model using clinical risk factors alone. IFNα2A in combination with established clinical risk factors may be useful for improving BCRL prognostication. Significance: The cytokine IFNα2A was identified as a potentially complementary biomarker to improve the stratification of high- and low-risk patients for BCRL. This will help enable earlier intervention to reduce long-term morbidity for those at high risk for lymphedema while minimizing burdensome interventions for those at low risk.
- 1 March 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (3) , 456-465
Open AccessIdentification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Lymphedema is a chronic complication of breast cancer treatment, and early intervention is crucial to reduce morbidity. This study evaluated the role of blood-based cytokine biomarkers in the prognostication of breast cancer–related lymphedema (BCRL) to improve risk prediction. A secondary analysis of inflammatory biomarkers for BCRL was performed using a previously published cohort of 147 patients with breast cancer who had undergone serum cytokine profiling during their treatment at the Princess Margaret Cancer Centre from 2010 to 2014. Prognostic cytokine variables for lymphedema were selected by regression analysis and independence from known clinical risk factors. Regression-based modeling was employed to integrate prognostic variables for the prediction of lymphedema occurrence. We identified the immunostimulatory cytokine IFNα2A as a potential biomarker for lymphedema development [OR, 3.10; 95% confidence interval (CI), 1.05–9.51; P = 0.042], independent from known clinical risk factors. Furthermore, Kaplan–Meier analysis demonstrated 3-year lymphedema-free survival of 95% (90%–100%) versus 85% (77%–94%) for below versus above median concentrations of IFNα2A (P = 0.026). In combination with an established clinical risk regression-based model, patients identified as high risk based on clinical factors alone were able to be correctly reclassified as low risk by IFNα2A in 31% (eight of 26) of cases. Our combined logistic regression model using both IFNα2A and clinical risk score achieved an AUC of 0.895 (95% CI, 0.796–0.971) and Brier score of 0.101 (95% CI, 0.061–0.149), representing a favorable improvement compared with the logistic regression model using clinical risk factors alone. IFNα2A in combination with established clinical risk factors may be useful for improving BCRL prognostication. Significance: The cytokine IFNα2A was identified as a potentially complementary biomarker to improve the stratification of high- and low-risk patients for BCRL. This will help enable earlier intervention to reduce long-term morbidity for those at high risk for lymphedema while minimizing burdensome interventions for those at low risk.